<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE1D1D4E-03D6-4D45-9048-74BFF08DA68A"><gtr:id>EE1D1D4E-03D6-4D45-9048-74BFF08DA68A</gtr:id><gtr:name>Peptinnovate Limited</gtr:name><gtr:address><gtr:line1>90 HIGH HOLBORN</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>WC1V 6XX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE1D1D4E-03D6-4D45-9048-74BFF08DA68A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>EE1D1D4E-03D6-4D45-9048-74BFF08DA68A</gtr:id><gtr:name>Peptinnovate Limited</gtr:name><gtr:address><gtr:line1>90 HIGH HOLBORN</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>WC1V 6XX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>150000.0</gtr:offerGrant><gtr:projectCost>200867.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131052"><gtr:id>6AF0D82A-D6FC-444C-AFCD-292B0CCA2E9D</gtr:id><gtr:title>Exploration and exploitation of a unique anti-inflammatory pathway derived from M.tuberculosis proteins</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131052</gtr:grantReference><gtr:abstractText>Tuberculosis (TB) bacteria are present in about 2 billion people worldwide; they have evolved over millenia to remain hidden in the body by producing proteins that subvert the host's immune system by interacting with the body's natural inflammatory processes. Peptinnovate?s innovative approach is to unlock the anti-inflammatory activity of these proteins and to develop new medicines for debilitating diseases. By building on nature's ingenuity Peptinnovate will create drug-like molecules to test in the clinical setting. The aim is to elucidate how the proteins are working by determining their molecular mechanism of action enabling the understanding of the novel anti-inflammatory pathway which will support further research and pave the way for potential new medicines.</gtr:abstractText><gtr:fund><gtr:end>2013-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>150000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131052</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>